19 results on '"Müller, Friederike"'
Search Results
2. Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo
- Author
-
Blank, Gregor, Welker, Christian, Sipos, Bence, Sonntag, Katja, Müller, Friederike, Eckert, Franziska, Seitz, Christian, Nadalin, Silvio, LaCorcia, Gina, Königsrainer, Alfred, Snell, Daniel, Handgretinger, Rupert, and Schilbach, Karin
- Published
- 2015
- Full Text
- View/download PDF
3. Die Behandlung des Chondroblastoms im Humeruskopf
- Author
-
Oenning, Sebastian, Schneider, Kristian Nikolaus, Gosheger, Georg, Theil, Christoph, Müller, Friederike, Deventer, Niklas, and Lübben, Timo
- Subjects
Adult ,Focal resurfacing ,Shoulder ,Shoulder Joint ,Kasuistiken ,Knorpelerkrankung ,Chondroblastoma ,Bone Neoplasms ,Fokale Rekonstruktion ,Humerus ,Schulter ,Curettage ,Young Adult ,Kürettage ,Orthopedics ,Treatment Outcome ,Humeral Head ,Humans ,Female ,Cartilage diseases - Abstract
Wir präsentieren den Fall einer 22-jährigen Patientin mit einem histopathologisch gesicherten Chondroblastom des rechten Humeruskopfes. Um bei der jungen und funktionell anspruchsvollen Patientin eine möglichst schonende und anatomische Rekonstruktion der humeralen Gelenkfläche zu erzielen, ohne dabei auf einen totalendoprothetischen Gelenkersatz zurückzugreifen, implantierten wir nach intraläsionaler Kürettage des Chondroblastoms eine HemiCAP®. Die sehr guten funktionellen Kurzzeitergebnisse zeigen, dass dieser Therapieansatz eine sehr gute Behandlungsoption darstellen kann. Video online Die Online-Version dieses Beitrags (10.1007/s00132-020-03958-w) enthält ein Video.
- Published
- 2020
4. From Degrammaticalisation to Regrammaticalisation? Current Changes in the Use of NEED
- Author
-
Müller, Friederike
- Published
- 2008
5. Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans
- Author
-
Weickert, Martin O, Roden, Michael, Isken, Frank, Hoffmann, Daniela, Nowotny, Peter, Osterhoff, Martin, Blaut, Michael, Alpert, Carl, Gögebakan, Özlem, Bumke-Vogt, Christiane, Mueller, Friederike, Machann, Jürgen, Barber, Tom M, Petzke, Klaus J, Hierholzer, Johannes, Hornemann, Silke, Kruse, Michael, Illner, Anne-Kathrin, Kohl, Angela, Loeffelholz, Christian V, Arafat, Ayman M, Möhlig, Matthias, and Pfeiffer, Andreas FH
- Published
- 2011
- Full Text
- View/download PDF
6. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma
- Author
-
Wallwiener Diethelm, Petersen Karen, Schneider Friederike, Müller Friederike, Scheble Veit, Neubauer Hans, Kurth Ralf, Fehm Tanja, Lengerke Claudia, Kanz Lothar, Fend Falko, Perner Sven, Bareiss Petra M, and Staebler Annette
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The SRY-related HMG-box family of transcription factors member SOX2 has been mainly studied in embryonic stem cells as well as early foregut and neural development. More recently, SOX2 was shown to participate in reprogramming of adult somatic cells to a pluripotent stem cell state and implicated in tumorigenesis in various organs. In breast cancer, SOX2 expression was reported as a feature of basal-like tumors. In this study, we assessed SOX2 expression in 95 primary tumors of postmenopausal breast cancer patients. Methods Samples from 95 patients diagnosed and treated at the University of Tuebingen Institute of Pathology and Women's Hospital were analyzed by immunohistochemistry for SOX2 expression in the primary tumor samples and in corresponding lymph node metastasis, where present. Furthermore, SOX2 amplification status was assessed by FISH in representative samples. In addition, eighteen fresh frozen samples were analyzed for SOX2, NANOG and OCT4 gene expression by real-time PCR. Results SOX2 expression was detected in 28% of invasive breast carcinoma as well as in 44% of ductal carcinoma in situ (DCIS) lesions. A score of SOX2 expression (score 0 to 3) was defined in order to distinguish SOX2 negative (score 0) from SOX2 positive samples (score 1-3) and among latter the subgroup of SOX2 high expressors (score 3 > 50% positive cells). Overall, the incidence of SOX2 expression (score 1-3) was higher than previously reported in a cohort of lymph node negative patients (28% versus 16.7%). SOX2 expression was detected across different breast cancer subtypes and did not correlate with tumor grading. However, high SOX2 expression (score 3) was associated with larger tumor size (p = 0.047) and positive lymph node status (0.018). Corresponding metastatic lymph nodes showed higher SOX2 expression and were significantly more often SOX2 positive than primary tumors (p = 0.0432). Conclusions In this report, we show that the embryonic stem cell factor SOX2 is expressed in a variety of early stage postmenopausal breast carcinomas and metastatic lymph nodes. Our data suggest that SOX2 plays an early role in breast carcinogenesis and high expression may promote metastatic potential. Further studies are needed to explore whether SOX2 can predict metastatic potential at an early tumor stage.
- Published
- 2011
- Full Text
- View/download PDF
7. Autoimmune Responses to mRNA Binding Proteins p62 and Koc in Diverse Malignancies
- Author
-
Zhang, Jian-Ying, Chan, Edward K.L., Peng, Xuan-Xian, Lu, Maolong, Wang, Xiao, Mueller, Friederike, and Tan, Eng M.
- Published
- 2001
- Full Text
- View/download PDF
8. Use of DNA arrays/microarrays in pancreatic research
- Author
-
Buchholz, Malte, Boeck, Wolfgang, Fensterer, Heiko, Müller, Friederike, Wenger, Christoph, Michl, Patrick, Adler, Guido, and Gress, Thomas M.
- Published
- 2001
- Full Text
- View/download PDF
9. In situ hybridization analysis of cytomegalovirus lytic infection in Kaposi's sarcoma associated with AIDS: A study of 14 autopsy cases
- Author
-
Hashimoto, Hiroshi, Müller, Hartmut, Müller, Friederike, Schmidts, Hans Ludwig, and Stutte, Hans Jochen
- Published
- 1987
- Full Text
- View/download PDF
10. Evaluation of Fear of Radiation and Isolation Before and After Radioiodine Therapy.
- Author
-
von Müller, Friederike, Happel, Christian, Reinhardt, Jörg, Kranert, Wolfgang Tilman, Bockisch, Benjamin, Gröner, Daniel, Ackermann, Hanns, and Grünwald, Frank
- Subjects
- *
FEAR , *RADIOACTIVE substances , *RADIATION protection , *QUESTIONNAIRES ,THERAPEUTIC use of iodine isotopes - Abstract
Background: Prior to undergoing radioiodine therapy (RIT), patients regularly have concerns about isolation on the ward (mandatory for RIT for at least 48 hours in Germany due to radiation protection legislation) as well as fear of the presence of radioactive substances. In this study, these fears were investigated before and after RIT. Methods: A questionnaire was developed for completion both before and after radioiodine therapy. Questions included: (i) 'Are you afraid of a therapy with radioactive substances?' (ii) 'Do you have reservations about contact with radioactive substances?' and (iii) 'Are you anxious about isolation?' Possible answers were made in a qualitative representation using a scale of 1-4 (4=full agreement, 3=mostly agreement, 2=partial agreement, and 1=no agreement). Further questions included, for example, sources of information used prior to therapy. A total of 209 patients treated by single or preplanned multiple RIT were surveyed over a period of 8 months (return 109). Analysis was done in subgroups according to age, education, disease, and number of RITs. Results: Question 1, 'Are you afraid of a therapy with radioactive substances?' showed a similar statistically relevant decline in each subgroup ( p<0.05), except for patients with multiple RIT ( p=0.81). Asked about the handling of radioactive substances and their perception about the safety in this regard, the entire collective showed a highly statistically significant ( p<0.01) decrease with little variability between the groups. The question concerning fear of isolation resulted in a significant decrease ( p<0.05) in all subgroups, except for patients with multiple RIT ( p=0.13). Analysis of sources of information before RIT showed that older patients preferred printed material and rarely used online resources, while younger patients used the internet more frequently, in addition to printed materials. Finally, most patients would undergo radioiodine therapy again (medical indication provided), with 54% fully agreeing and only 4% not agreeing. Conclusions: The survey demonstrates a reduction in concerns about nuclear radiation, use of unsealed radioactive materials, and isolation on the ward after RIT. Surprisingly, concerns rise again before a subsequent therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.
- Author
-
Lengerke, Claudia, Fehm, Tanja, Kurth, Ralf, Neubauer, Hans, Scheble, Veit, Müller, Friederike, Schneider, Friederike, Petersen, Karen, Wallwiener, Diethelm, Kanz, Lothar, Fend, Falko, Perner, Sven, Bareiss, Petra M., and Staebler, Annette
- Subjects
EMBRYONIC stem cells ,BREAST cancer ,SOMATIC cells ,IMMUNOHISTOCHEMISTRY ,LYMPH nodes - Abstract
Background: The SRY-related HMG-box family of transcription factors member SOX2 has been mainly studied in embryonic stem cells as well as early foregut and neural development. More recently, SOX2 was shown to participate in reprogramming of adult somatic cells to a pluripotent stem cell state and implicated in tumorigenesis in various organs. In breast cancer, SOX2 expression was reported as a feature of basal-like tumors. In this study, we assessed SOX2 expression in 95 primary tumors of postmenopausal breast cancer patients. Methods: Samples from 95 patients diagnosed and treated at the University of Tuebingen Institute of Pathology and Women's Hospital were analyzed by immunohistochemistry for SOX2 expression in the primary tumor samples and in corresponding lymph node metastasis, where present. Furthermore, SOX2 amplification status was assessed by FISH in representative samples. In addition, eighteen fresh frozen samples were analyzed for SOX2, NANOG and OCT4 gene expression by real-time PCR. Results: SOX2 expression was detected in 28% of invasive breast carcinoma as well as in 44% of ductal carcinoma in situ (DCIS) lesions. A score of SOX2 expression (score 0 to 3) was defined in order to distinguish SOX2 negative (score 0) from SOX2 positive samples (score 1-3) and among latter the subgroup of SOX2 high expressors (score 3 > 50% positive cells). Overall, the incidence of SOX2 expression (score 1-3) was higher than previously reported in a cohort of lymph node negative patients (28% versus 16.7%). SOX2 expression was detected across different breast cancer subtypes and did not correlate with tumor grading. However, high SOX2 expression (score 3) was associated with larger tumor size (p = 0.047) and positive lymph node status (0.018). Corresponding metastatic lymph nodes showed higher SOX2 expression and were significantly more often SOX2 positive than primary tumors (p = 0.0432). Conclusions: In this report, we show that the embryonic stem cell factor SOX2 is expressed in a variety of early stage postmenopausal breast carcinomas and metastatic lymph nodes. Our data suggest that SOX2 plays an early role in breast carcinogenesis and high expression may promote metastatic potential. Further studies are needed to explore whether SOX2 can predict metastatic potential at an early tumor stage. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
12. Influence of Losigamone on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Volunteers.
- Author
-
Dienel, Angelika, Klement, Stephan, and Müller, Friederike
- Subjects
ANTICONVULSANTS ,MUSCLE relaxants ,ORAL contraceptives ,CONTRACEPTIVE drugs ,DRUG interactions ,DRUG side effects - Abstract
Objectives: The influence of the new antiepileptic drug losigamone (CAS 11285644-7 / 123783-52-8) on the pharmacokinetics of a combined oral contraceptive containing ethinylestradiol (CAS 57-63-6) and levonorgestrel (CAS 797-63-7) was investigated in 16 healthy women. Methods: This phase I study consisted of 3 periods with an uncontrolled first period and a double-blind, placebo-controlled, cross-over design in the second and third period. All subjects received a single dose of 200 mg losigamone (1 tablet) in period 1 (on day 14) as well as multiple doses of losigamone (3 tablets = 600 mg per day) or placebo for 15 days in periods 2 and 3. During all three periods an oral contraceptive containing 30 µg ethinylestradiol and 150 µg levonorgestrel was given. Single-dose pharmacokinetics was investigated on day 14 of period 1. Multiple-dose pharmacokinetic investigations were performed on day 15 of periods 2 and 3. The samples were assayed to derive pharmacokinetic data of ethinylestradiol and levonorgestrel. In addition, the concentrations of losigamone racemate (AO-33) and its enantiomers AO-242 and AO-294 were determined in these samples. Results: The mean values of the pharmacokinetic parameters AUC and C
max of ethinylestradiol and levonorgestrel after multiple-dose treatment with losigamone or placebo were quite similar and met the criteria for bioequivalence. The 90% confidence intervals of the logtransformed ratios of the geometric means of the primary pharmacokinetic variables were included in the respective acceptance ranges of 80% to 125% (AUC) and 70% to 143% (Cmax ). Conclusions: The study demonstrated that multiple doses of losigamone did not influence the multiple dose kinetics of ethinylestradiol and levonorgestrel. The single- and multiple-dose kinetics of 200 mg losigamone and its enantiomeres did not differ from each other in a significant way. The combination of losigamone and the combined oral contraceptive was well tolerated and no serious adverse events occurred. It can be stated that the antiepileptic drug losigamone and the combined contraceptive do not interact each others metabolism. [ABSTRACT FROM AUTHOR]- Published
- 2004
13. Angiotensin II controls angiotensinogen secretion at a pretranslational level.
- Author
-
Klett, Christoph, Hellmann, Waltraud, Müller, Friederike, Suzuki, Fumiaki, Nakanishi, Shigetada, Ohkubo, Hiroaki, Ganten, Detlef, and Hackenthal, Eberhard
- Published
- 1988
- Full Text
- View/download PDF
14. 42. The mood stabilizer valproic acid down regulates neuronal cyclooxygenase-2 expression: Central role of nuclear factor-kappa B after long-term, but not short-term treatment
- Author
-
Singh, Vikramjeet, Caballero, Francisco J., Calzado, Marco A., Candelario-Jalil, Eduardo, Müller, Friederike von, Ottomeyer, Caroline, Hüll, Michael, Munoz, Eduardo, Lieb, Klaus, and Fiebich, Bernd L.
- Published
- 2009
- Full Text
- View/download PDF
15. Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.
- Author
-
Schilbach, Karin, Alkhaled, Mohammed, Welker, Christian, Eckert, Franziska, Blank, Gregor, Ziegler, Hendrik, Sterk, Marco, Müller, Friederike, Sonntag, Katja, Wieder, Thomas, Braumüller, Heidi, Schmitt, Julia, Eyrich, Matthias, Schleicher, Sabine, Seitz, Christian, Erbacher, Annika, Pichler, Bernd J, Müller, Hartmut, Tighe, Robert, and Lim, Annick
- Subjects
INTERLEUKIN-12 ,CANCER immunotherapy ,RHABDOMYOSARCOMA ,CYTOKINES ,MYOBLASTS - Abstract
Stimulating the immune system to attack cancer is a promising approach, even for the control of advanced cancers. Several cytokines that promote interferon-γ-dominated immune responses show antitumor activity, with interleukin 12 (IL-12) being of major importance. Here, we used an antibody-IL-12 fusion protein (NHS-IL12) that binds histones of necrotic cells to treat human sarcoma in humanized mice. Following sarcoma engraftment, NHS-IL12 therapy was combined with either engineered IL-7 (FcIL-7) or IL-2 (IL-2MAB602) for continuous cytokine bioavailability. NHS-IL12 strongly induced innate and adaptive antitumor immunity when combined with IL-7 or IL-2. NHS-IL12 therapy significantly improved survival of sarcoma-bearing mice and caused long-term remissions when combined with IL-2. NHS-IL12 induced pronounced cancer cell senescence, as documented by strong expression of senescence-associated p16INK4aand nuclear translocation of p-HP1γ, and permanent arrest of cancer cell proliferation. In addition, this cancer immunotherapy initiated the induction of myogenic differentiation, further promoting the hypothesis that efficient antitumor immunity includes mechanisms different from cytotoxicity for efficient cancer controlin vivo. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
16. Interfaces in partly compatible polymer mixtures: a Monte-Carlo simulation approach
- Author
-
Binder, Kurt, Schmid, Marcus Müller, Friederike, and Werner, Andreas
- Published
- 1998
- Full Text
- View/download PDF
17. Chronic graft-versus-host-disease in CD34+-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease.
- Author
-
Sonntag, Katja, Eckert, Franziska, Welker, Christian, Müller, Hartmut, Müller, Friederike, Zips, Daniel, Sipos, Bence, Klein, Reinhild, Blank, Gregor, Feuchtinger, Tobias, Schumm, Michael, Handgretinger, Rupert, and Schilbach, Karin
- Subjects
- *
GRAFT versus host disease , *CD34 antigen , *DISEASE susceptibility , *LABORATORY mice , *HAPLOTYPES , *HLA histocompatibility antigens - Abstract
Chronic graft-versus-host disease (cGVHD) is a significant hurdle to long-term hematopoietic stem-cell transplantation success. Insights into the pathogenesis and mechanistical investigations of novel therapeutic strategies are limited as appropriate animal models are missing. The immunodeficient NSG mouse – when humanized with human bone marrow, fetal liver and thymus (BLT NSG) – is prone for cGVHD, yet mainly affects the skin. In contrast, the NSG mouse humanized exclusively with CD34 + -selected, CD3 + -depleted stem cells (CD34 + NSG) has neither been described for acute nor chronic GVHD so far. This is the first report about the development of systemic autoimmune cGVHD ≥24 weeks post stem cell receipt involving lung, liver, skin, gingiva and intestine in two NSG cohorts humanized with CD34 + grafts from different donors. Affected mice presented with sclerodermatous skin, fibrotic lung, severe hepatitis, and massive dental malformation/loss. CD4 + -dominated, T H 2-biased, bulky T-cell infiltrates featured highly skewed T cell receptor (TCR) repertoires, clonal expansions, and autoreactive TCRs. In affected tissues profibrotic IL-13 and -4 dominated over T H 1 cytokines IFN-γ and TNF-α. Thus, the time point of manifestation and the phenotype match human systemic pleiotropic sclerodermatous GVHD. The CD34 + NSG-model's intrinsic deficiency of thymus, thymus-derived regulatory T cells (nTreg) and B cells emphasizes the role of the genetic polymorphism and the cytokines in the pathogenesis of cGVHD. Importantly, the only factor discriminating diseased versus non-diseased CD34 + NSG cohorts were two risk HLA haplotypes that in human mediate susceptibility for autoimmune disease (psoriasis). Thus, the CD34 + NSG model may serve as a platform for addressing issues related to the pathophysiology and treatment of human autoimmunity and chronic GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Percutaneous-transhepatic-endoscopic rendezvous procedures are effective and safe in patients with refractory bile duct obstruction.
- Author
-
Bokemeyer A, Müller F, Niesert H, Brückner M, Bettenworth D, Nowacki T, Beyna T, Ullerich H, and Lenze F
- Subjects
- Aged, Cholangitis etiology, Drainage, Female, Humans, Male, Middle Aged, Pancreatitis etiology, Peritonitis etiology, Pneumothorax etiology, Postoperative Hemorrhage etiology, Retrospective Studies, Biliary Tract Surgical Procedures adverse effects, Cholangiopancreatography, Endoscopic Retrograde adverse effects, Cholangiopancreatography, Endoscopic Retrograde methods, Cholestasis diagnostic imaging
- Abstract
Background: Percutaneous-transhepatic-endoscopic rendezvous procedures (PTE-RVs) are rescue approaches used to facilitate biliary drainage., Objective: The objective of this article is to evaluate the safety and the technical success of PTE-RVs in comparison with those of percutaneous transhepatic cholangiographies (PTCs)., Methods: Percutaneous procedures performed over a 10-year period were retrospectively analyzed in a single-center cohort. Examinations were performed because of a previous or expected failure of standard endoscopic methods including endoscopic retrograde cholangiography (ERC) or balloon-assisted ERC to achieve biliary access., Results: In total, 553 percutaneous procedures including 163 PTE-RVs and 390 PTCs were performed. Overall, 71.3% of the patients suffered from malignant disease with pancreas-carcinoma (32.8%) and cholangio-carcinoma (19.0%) as the most frequent, while 28.7% of the patients suffered from benign disease. Many patients had a postoperative change in bowel anatomy (50.8%).PTC had a higher technical success rate (89.7%); however, the technical success rate of PTE-RVs was still high (80.4%; p < 0.003). Overall complications occurred in 23.5% of all procedures. Significantly fewer complications occurred after performing PTE-RVs than after PTCs (16.6% vs 26.4%; p = 0.037)., Conclusion: Beside a high technical efficacy of PTE-RVs, significantly fewer complications occur following PTE-RVs than following PTCs; thus, PTE-RV should be preferred over PTC alone in selected patients.
- Published
- 2019
- Full Text
- View/download PDF
19. Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
- Author
-
Dienel A, Klement S, and Müller F
- Subjects
- Adult, Anticonvulsants adverse effects, Area Under Curve, Contraceptives, Oral, Combined adverse effects, Drug Interactions, Ethinyl Estradiol pharmacokinetics, Female, Furans adverse effects, Humans, Levonorgestrel pharmacokinetics, Stereoisomerism, Anticonvulsants pharmacology, Contraceptives, Oral, Combined pharmacokinetics, Furans pharmacology
- Abstract
Objectives: The influence of the new antiepileptic drug losigamone (CAS 112856-44-7/123783-52-8) on the pharmacokinetics of a combined oral contraceptive containing ethinylestradiol (CAS 57-63-6) and levonorgestrel (CAS 797-63-7) was investigated in 16 healthy women., Methods: This phase I study consisted of 3 periods with an uncontrolled first period and a double-blind, placebo-controlled, cross-over design in the second and third period. All subjects received a single dose of 200 mg losigamone (1 tablet) in period 1 (on day 14) as well as multiple doses of losigamone (3 tablets = 600 mg per day) or placebo for 15 days in periods 2 and 3. During all three periods an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel was given. Single-dose pharmacokinetics was investigated on day 14 of period 1. Multiple-dose pharmacokinetic investigations were performed on day 15 of periods 2 and 3. The samples were assayed to derive pharmacokinetic data of ethinylestradiol and levonorgestrel. In addition, the concentrations of losigamone racemate (AO-33) and its enantiomers AO-242 and AO-294 were determined in these samples., Results: The mean values of the pharmacokinetic parameters AUC and Cmax of ethinylestradiol and levonorgestrel after multiple-dose treatment with losigamone or placebo were quite similar and met the criteria for bioequivalence. The 90% confidence intervals of the log-transformed ratios of the geometric means of the primary pharmacokinetic variables were included in the respective acceptance ranges of 80% to 125% (AUC) and 70% to 143% (Cmax)., Conclusions: The study demonstrated that multiple doses of losigamone did not influence the multiple dose kinetics of ethinylestradiol and levonorgestrel. The single- and multiple-dose kinetics of 200 mg losigamone and its enantiomeres did not differ from each other in a significant way. The combination of losigamone and the combined oral contraceptive was well tolerated and no serious adverse events occurred. It can be stated that the antiepileptic drug losigamone and the combined contraceptive do not interact each others metabolism.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.